Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus bevacizumab versus capecitabine plus bevacizumab in previously untreated metastatic colorectal cancer not eligible for intensive therapy
2015-004544-18Phase 2Completed
- Sponsor
- Servier
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing TAS-102 + bevacizumab with Capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jan 2016; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-004544-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004544-18.